Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 06 jun 2018 - 07:00
- Statutory name argenx SE
- Title argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
|201806060000000001_argenx receives feedback from FDA in end.pdf|
Date last update: 18 January 2019